Can Amylin Weight-Loss Drugs Compete in a World of GLP-1s?
Wall Street remains skeptical, but developers of amylin-based drugs say recent clinical trial results point to a real opening in the weight-loss market.
GLP-1 receptor agonists like semaglutide and tirzepatide have become the dominant force in obesity treatment, but a separate class of weight-loss drugs built around the hormone amylin is quietly pushing for a seat at the table. The catch? Wall Street isn’t buying it yet.
A new report from Chemical & Engineering News examines where amylin-based therapies stand today, why investors are cool on the data, and why the researchers and companies developing these drugs think the story isn’t over.
Details
Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells. It plays a role in slowing gastric emptying, suppressing glucagon, and signaling fullness to the brain. In other words, it works on some of the same pathways that make GLP-1 drugs effective, just through different mechanisms.
Pramlintide, an amylin analog, already has FDA approval for diabetes management, which means this class isn’t unproven. But newer amylin-targeting compounds are being developed specifically for weight loss, and that’s where comparisons with GLP-1s get complicated.
The central tension in the C&EN piece is that amylin drugs have produced weight loss in clinical trials, but the results haven’t matched what semaglutide and tirzepatide routinely deliver. GLP-1 drugs can produce 15 to 22 percent body weight reductions in large trials. Amylin-based candidates haven’t consistently hit those figures in publicly available data so far.
Developers argue that head-to-head comparisons miss the point. Amylin and GLP-1 drugs work through distinct mechanisms, which means there’s a real scientific rationale for combining them rather than choosing one or the other. Some programs are already exploring dual and combination approaches. Cagrilintide, an amylin analog paired with semaglutide in Novo Nordisk’s CagriSema program, is probably the most prominent example. Early results from that combination have shown weight loss figures that exceed either drug alone.
Where Wall Street gets skeptical is with standalone amylin therapies. If GLP-1 monotherapy already produces dramatic results, the commercial case for a separate amylin-only product is harder to make. Investors want to see strong differentiation, and clinical readouts so far haven’t provided that knockout argument.
Developers counter that the obesity treatment market is large enough for multiple mechanisms to coexist. They also point to patient tolerability as a potential differentiating factor. GLP-1 drugs carry a well-documented side effect burden, particularly nausea and vomiting during early dose escalation. Some researchers believe amylin-based drugs may offer a smoother profile for certain patients, though the data on that is still developing.
There’s also an access angle. GLP-1 drugs face serious supply constraints and high costs. If amylin-based options can demonstrate meaningful efficacy at competitive price points, there could be a real-world opening even if the headline weight-loss numbers are lower.
Why It Matters
The obesity drug market is one of the most commercially significant in pharmaceutical history right now, and competition to find the next important mechanism is intense. Amylin’s situation shows how a scientifically credible target can struggle to cut through when a dominant drug class already owns the conversation.
For patients and clinicians, having more mechanistic options eventually means better matching of therapies to individual biology. Not everyone responds the same way to GLP-1 drugs, and tolerability differences between patients are real. A complementary mechanism that works differently could fill genuine gaps in care.
What’s Next
The near-term focus will be on how combination trials involving amylin analogs perform. If programs like CagriSema continue to post strong results, it will validate amylin as a meaningful component of next-generation obesity treatment, even if standalone amylin drugs remain a harder commercial sell.
Standalone programs still need more clinical evidence before the investment case changes materially. Larger, longer trials with clear efficacy and safety profiles will be necessary to shift skepticism in any meaningful way.
Related Reading
Original Source
cen.acs.org →